NYSE$ELV

Elevance Health Inc · Q1 2021 earnings

Q1 2021 earnings · · Investor relations

Briefing

Anthem reported strong financial performance in the first quarter of 2021, driven by strong execution and a focus on supporting communities through the pandemic.

Anthem's first quarter 2021 results reflected strong financial performance with operating revenue growth of 9.0% to $32.1 billion and adjusted net income of $7.01 per share. Medical enrollment increased to 43.5 million members. The company raised its full year adjusted net income outlook to greater than $25.10 per share.

  • GAAP net income was $6.71 per share, including net negative adjustment items of $0.30 per share; adjusted net income was $7.01 per share.
  • Operating revenue grew by 9.0%, or 10.7% adjusted for the repeal of the health insurance tax, over the prior year quarter to $32.1 billion.
  • Medical enrollment increased by 1.4 million members year over year and 596 thousand members sequentially to 43.5 million members.
  • The company is raising full year adjusted net income outlook from greater than $24.50 per share to greater than $25.10 per share.

Headline financials

Total Revenue

$32.4B

Previous: $29.6B+9.3%
EPS (adj)

$7.01

Previous: $6.48+8.2%
Total Medical Membership

43.5M

Previous: 42.1M+3.2%
Capital Expenditures

-$204M

Previous: -$204M+0.0%
Free Cash Flow

$1.46B

Previous: $1.32B+10.8%
Net Income

$1.67B

Previous: $1.52B+9.3%
Operating Income

$2.16B

Previous: $2.19B-1.5%
Gross Profit

$30.1B

Previous: $27.6B+8.8%
Cash & Equivalents

$9.33B

Previous: $5.35B+74.5%
Total Assets

$95.7B

Previous: $82.4B+16.1%
Stock-Based Comp

$64M

Previous: $67M-4.5%

Revenue & EPS history

Elevance Health · Revenue · Quarterly

$32.4B

Q1 2021+9.3%vs Q1 2020
Beat estimate in 13 of 16 quarters(81%)
ActualEstimate

Revenue by segment

Elevance Health · $36.7B total across 1 segment · Q3 2023

  • Health Benefits
    $36.7B

Forward guidance

Anthem is raising its full year 2021 outlook. GAAP net income is now expected to be greater than $24.05 per share, and adjusted net income is expected to be greater than $25.10 per share. Medical membership is expected to be in the range of 44.1 - 44.7 million. Operating revenue is expected to be approximately $135.1 billion.

Tailwinds

  • GAAP net income is now expected to be greater than $24.05 per share, including approximately $1.05 per share of net unfavorable items.
  • Adjusted net income is expected to be greater than $25.10 per share.
  • Medical membership is expected to be in the range of 44.1 - 44.7 million.
  • Risk-based membership is expected to be in the range of 18.6 - 19.0 million.
  • Fee-based membership is expected to be in the range of 25.5 - 25.7 million.

Headwinds

  • Benefit expense ratio is expected to be in the range of 88.0% plus or minus 50 basis points.
  • SG&A ratio is expected to be 10.8% plus or minus 50 basis points.
  • Operating cash flow is expected to be greater than $5.7 billion.
  • Investment income is now expected to be $970 million.
  • Interest expense is now expected to be $820 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2021

Historical avgQ1 2021

-0.1%

Avg return

Earnings day

+0.8%

Avg return

5 days after

+2.4%

Avg return

30 days after

54%

25 / 46 earnings

Positive

+11.1%

Q4 2018

Best reaction

-15.0%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.3%+8.5%+20.3%
Q4 2025+5.1%+5.9%-0.9%
Q3 2025-1.1%-3.3%-11.3%
Q2 2025+0.3%+6.0%+5.9%
Q1 2025+2.1%+3.7%-5.5%
Q4 2024+2.9%+3.8%-1.4%
Q3 2024-15.0%-15.5%-19.4%
Q2 2024-8.7%-8.9%-1.7%
Q1 2024+4.1%+4.7%+7.6%
Q4 2023+1.8%+3.0%+8.9%
Q3 2023-0.6%-3.0%-0.6%
Q2 2023+7.2%+6.2%+4.3%
Q1 2023-5.8%-4.2%-5.2%
Q4 2022+3.6%+2.2%-0.1%
Q3 2022+2.0%+10.1%+3.6%
Q2 2022-7.6%-5.3%+1.2%
Q1 2022+1.1%-2.0%-4.7%
Q4 2021-0.8%+0.4%+3.3%
Q3 2021+9.3%+10.4%+5.5%
Q2 2021-1.4%-2.9%-3.1%
Q1 2021-0.5%-1.1%+3.7%
Q4 2020-3.8%-6.4%-3.0%
Q3 2020-8.6%-6.9%+4.7%
Q2 2020+4.5%+2.1%+4.5%
Q1 2020+4.7%+1.0%+9.7%
Q4 2019-8.4%-8.2%-11.4%
Q3 2019-0.3%+2.9%+12.1%
Q2 2019-2.9%-1.4%-13.9%
Q1 2019+2.1%+6.2%+10.6%
Q4 2018+11.1%+11.6%+12.8%
Q3 2018+0.2%+1.4%+9.3%
Q2 2018+0.4%+2.5%+7.8%
Q1 2018+5.3%+4.9%+3.3%
Q4 2017+0.2%-5.3%-4.3%
Q3 2017+6.0%+7.3%+12.9%
Q2 2017-3.7%-2.3%+1.1%
Q1 2017+3.4%+3.9%+6.2%
Q4 2016+2.3%+1.7%+7.7%
Q3 2016+2.2%+5.2%+23.6%
Q2 2016-3.4%-7.3%-9.2%
Q1 2016-2.1%
Q4 2015-8.2%
Q3 2015-2.3%
Q2 2015+0.4%
Q1 2015-2.1%
Q4 2014-0.5%
Q3 2014
Q2 2014
Q1 2014
Q4 2013
Q3 2013
Q2 2013
Q1 2013
Q4 2011
Q4 2012
Q3 2012
Q2 2012
Q1 2012
Q3 2011
Q2 2011
Q1 2011
Q4 2010
Q3 2010
Q2 2010
Q1 2009
Q1 2010
Q4 2007
Q4 2009
Q3 2009
Q3 2008
Q4 2008
Q2 2009
Q2 2008

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro